The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes

• Published in: Scientific reports Vol. 12; no. 1; pp. 1896 - 8
• Main Authors: Okura, Tsuyoshi, Fujioka, Yohei, Nakamura, Risa, Kitao, Sonoko, Ito, Yuichi, Anno, Mari, Matsumoto, Kazuhisa, Shoji, Kyoko, Matsuzawa, Kazuhiko, Izawa, Shoichiro, Okura, Hiroko, Ueta, Etsuko, Kato, Masahiko, Imamura, Takeshi, Taniguchi, Shin-Ichi, Yamamoto, Kazuhiro
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 03.02.2022; Nature Publishing Group UK; Nature Portfolio
• Subjects: Biomarkers - blood; Blood Glucose - drug effects; Blood Glucose - metabolism; Body composition; Body weight; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Fatty liver; Female; Gastric Inhibitory Polypeptide - blood; Glucagon; Glucagon - blood; Glucagon-Like Peptide 1 - blood; Glucose; Glucosides - adverse effects; Glucosides - therapeutic use; Humans; Insulin; Insulin - blood; Insulin Resistance; Insulin secretion; Japan; Liver - drug effects; Liver - metabolism; Male; Middle Aged; Patients; Peptides; Sodium; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Thiophenes - adverse effects; Thiophenes - therapeutic use; Time Factors; Treatment Outcome; Japan
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-05704-y

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment is a therapeutic approach for type 2 diabetes mellitus (T2DM). Some reports have shown that SGLT2i treatment improves insulin resistance; however, few studies have evaluated insulin resistance by the glucose clamp method. Hepatic insulin clearance (HIC) is a new pathophysiological mechanism of T2DM. The effect of SGLT2i treatment on hepatic insulin clearance and insulin resistance is not well known. We investigated the effect of SGLT2i treatment on insulin resistance, insulin secretion, incretin levels, body composition, and hepatic insulin clearance. We conducted a meal tolerance test (MTT) and a hyperinsulinemic-euglycemic clamp test in 9 T2DM patients. Ipragliflozin (50 mg/day) was administered, and the MTT and clamp test were performed after 4 months. We calculated HIC as the postprandial C-peptide AUC-to-insulin AUC ratio. We also measured GLP-1, GIP, and glucagon levels during the MTT. Body weight and HbA1c were decreased, although not significantly, after 4 months of treatment. Postprandial glucose, fasting insulin and postprandial insulin were significantly decreased. Insulin resistance with the glucose clamp was not changed, but the HOMA-IR and insulin sensitivity indices were significantly improved. Incretin and glucagon levels were not changed. Hepatic insulin clearance was significantly increased, but whole-body insulin clearance was not changed. The FIB-4 index and fatty liver index were significantly reduced. The HOMA-beta and insulinogenic indices were not changed, but the C-peptide index was significantly increased. Although the number of patients was small, these results suggested that SGLT2i treatment improved liver function, decreased hepatic insulin resistance, and increased hepatic insulin clearance, despite the small weight reduction.